Golumbeski George

Director at ENTA

Sold, on record
$2.2M
Dollars the filings state
Form 4 sales
2
Latest Mar 4, 2019
Form 144 notices
0
Proposed sales
Quarters with a sale
0 of the last 8
No sale in two years
Companies
1
Filed as an executive or holder

Companies

  • ENTAENANTA PHARMACEUTICALS INCDirector

Sales by reason

0
Routine
0
Plan not stated
0
No plan
2
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per year, every sale on record.

Sales chart range

Timeline

  1. Mar 4, 2019Unusual

    ENTA

    Sold 100% of their holdings

    $962k9,280 shares at $103.65

    Filed Mar 6, 2019Form 4

  2. Feb 12, 2019Unusual

    ENTA

    Sold 100% of their holdings

    $1.2M13,500 shares at $90.06

    Filed Feb 13, 2019Form 4

2 of 2

Every transaction

Every transaction on a Form 4 or Form 5 by Golumbeski George
TradedFiledStockRoleWhatAmountPriceValueHeld afterSource
Jun 3, 2026Jun 5, 2026ABOSDirectorAwardedStock Option (right to buy)53,25053,250SEC
Jun 3, 2026Jun 5, 2026ABOSDirectorAwarded35,50035,500SEC
May 29, 2026Jun 2, 2026STTKDirectorAwardedStock Option (Right to Buy)81,00081,000SEC
Dec 5, 2025Dec 5, 2025MURADirectorReturned to the companyStock Option (right to buy)23,9710SEC
Nov 6, 2025Nov 10, 2025ABOSDirectorAwardedStock Option (right to buy)50,00050,000SEC
Jul 31, 2025Jul 31, 2025Sage Therapeutics, Inc.DirectorTendered8,0000SEC
Jul 31, 2025Jul 31, 2025Sage Therapeutics, Inc.DirectorReturned to the companyStock Option (Right to Buy)35,0930SEC
Jul 14, 2025Jul 16, 2025STTKDirectorAwardedStock Option (Right to Buy)33,15033,150SEC
Jun 11, 2025Jun 13, 2025Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)21,50021,500SEC
Jun 11, 2025Jun 13, 2025MURADirectorAwardedStock Option (right to buy)8,6378,637SEC
Jan 3, 2025Jan 6, 2025Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)13,59313,593SEC
Jul 30, 2024Jul 31, 2024MURADirectorAwardedStock Option (right to buy)15,33415,334SEC
Jun 21, 2024Jun 21, 2024STTKDirectorAwardedStock Option (Right to Buy)27,70027,700SEC
Jun 10, 2024Jun 11, 2024Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)12,50012,500SEC
Jan 3, 2024Jan 4, 2024Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)3,4953,495SEC
Jun 15, 2023Jun 16, 2023Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)10,00010,000SEC
May 26, 2023May 31, 2023STTKDirectorAwardedStock Option (Right to Buy)40,25840,258SEC
Jan 4, 2023Jan 5, 2023Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)2,1082,108SEC
Jun 16, 2022Jun 17, 2022Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)9,9479,947SEC
Jun 8, 2022Jun 10, 2022STTKDirectorAwardedStock Option (Right to Buy)40,25840,258SEC
May 5, 2022May 9, 2022Sage Therapeutics, Inc.DirectorBought8,000$31.45$252k8,000SEC
Apr 26, 2022Apr 27, 2022STTKDirectorBought28,330$3.63$103k54,613SEC
Apr 22, 2022Apr 26, 2022STTKDirectorBought26,283$3.69$97k26,283SEC
Jan 4, 2022Jan 5, 2022Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)1,6381,638SEC
Jun 19, 2021Jun 22, 2021STTKDirectorAwardedStock Option (Right to Buy)3,4343,434SEC
Jun 10, 2021Jun 11, 2021Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)10,00010,000SEC
Jan 5, 2021Jan 6, 2021Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)832832SEC
Dec 22, 2020Dec 28, 2020STTKDirectorAwardedStock Option (Right to Buy)1,2861,286SEC
Jul 6, 2020Jul 8, 2020CRBPDirectorAwardedStock Option(right to buy)81,00081,000SEC
Jun 9, 2020Jun 11, 2020Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)10,00010,000SEC
Feb 26, 2020Feb 28, 2020ENTADirectorAwardedStock Option (right to buy)10,00010,000SEC
Jan 3, 2020Jan 7, 2020Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)976976SEC
Jun 5, 2019Jun 6, 2019Sage Therapeutics, Inc.DirectorAwardedStock Option (Right to Buy)10,00010,000SEC
Mar 4, 2019Mar 6, 2019ENTADirectorSold9,280$103.65$962k0SEC
Mar 4, 2019Mar 6, 2019ENTADirectorExercised or settledStock Option (Right to Buy)9,2800SEC
Mar 4, 2019Mar 6, 2019ENTADirectorExercised options9,280$36.61$340k9,280SEC
Feb 28, 2019Mar 1, 2019ENTADirectorAwardedStock Option (right to buy)5,0005,000SEC
Feb 12, 2019Feb 13, 2019ENTADirectorSold13,500$90.06$1.2M0SEC
Feb 12, 2019Feb 13, 2019ENTADirectorExercised or settledStock Option (Right to Buy)13,5000SEC
Feb 12, 2019Feb 13, 2019ENTADirectorExercised options13,500$27.49$371k11,228SEC
Jan 22, 2019Jan 24, 2019Sage Therapeutics, Inc.DirectorAwardedStock Options (Right to buy)20,00020,000SEC
Feb 28, 2018Mar 5, 2018ENTADirectorAwardedStock Option (right to buy)7,5007,500SEC
Feb 16, 2017Feb 21, 2017ENTADirectorAwardedStock Option (right to buy)7,5007,500SEC
Feb 11, 2016Feb 12, 2016ENTADirectorAwardedStock Option (right to bury)6,0006,000SEC
Feb 19, 2015Feb 20, 2015ENTADirectorAwardedStock Option (right to bury)6,0006,000SEC
Feb 7, 2014Feb 11, 2014ENTADirectorAwardedStock Option (right to bury)9,2809,280SEC

Sales and notices (2)

Form 144 notices and Form 4 sales by Golumbeski George
Source
Mar 4, 2019Mar 6, 2019ENTADirectorForm 4 sale9,280$962k100.0%UnusualSEC
Feb 12, 2019Feb 13, 2019ENTADirectorForm 4 sale13,500$1.2M100.0%UnusualSEC